Rituximab
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Rituximab?
| |
| Therapeutic monoclonal antibody | |
| Source | chimeric (mouse/human) |
| Target | CD20 |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C6416H9874N1688O1987S44 |
| Mol. mass | 143859.7 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Metabolism | ? |
| Half life | 30 to 400 hours (varies by dose and length of treatment) |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) (no adequate human studies) |
| Legal status | |
| Routes | intravenous infusion only (never bolus or "push") |
|
WikiDoc Resources for Rituximab | |
|
Articles | |
|---|---|
|
Most recent articles on Rituximab | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Rituximab at Clinical Trials.gov Clinical Trials on Rituximab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Rituximab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Rituximab Discussion groups on Rituximab Directions to Hospitals Treating Rituximab Risk calculators and risk factors for Rituximab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Rituximab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Rituximab, sold under the trade names Rituxan® and MabThera®, is a chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders.
History
Rituximab was developed by IDEC Pharmaceuticals and initially approved by the FDA in 1997 for lymphoma that was refractory to other chemotherapy regimens. The original approval followed the availability of the McLaughlin et al[1] study data. It now is standard therapy in the initial treatment of aggressive lymphomas (e.g. diffuse large B cell lymphoma) in combination with CHOP chemotherapy. It is currently co-marketed by Biogen Idec and Genentech in the U.S. market and Roche in the EU.
Uses
Rituximab depletes B cells, and therefore is used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.
Neoplastic diseases
Most patients taking rituximab have a neoplastic disease such as leukemia or lymphoma.
Autoimmune diseases
Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.[1] (FDA-approved for use in combination with methotrexate (MTX) for reducing signs and symptoms in adult patients with moderately- to severely-active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF-alpha therapies.) There is evidence for efficacy in a range of other autoimmune diseases, including idiopathic autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (ITP)[1][1], Evans syndrome[1], vasculitis, bullous skin disorders, type 1 diabetes mellitus, Sjogren's syndrome, Devic's Syndrome and systemic lupus erythematosus, although there are significant concerns about PML infection in SLE patients[3].
Anti-rejection treatment for organ transplants
Rituximab is now being used in the management of Renal Transplant recipients. This drug is especially useful in transplants involving incompatible blood groups. It is also used as induction therapy in highly sensitized patients going for renal transplantation.
Mechanism
The antibody binds to the cluster of differentiation 20 (CD20). CD20 is widely expressed on B-cells. It does not shed, modulate or internalise. Although the function of CD20 is relatively unknown it has been indicated that CD20 could play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration and allowing activation of B cells.
The exact mode of action of rituximab is unclear, but the following effects have been found:[1]
- The Fc portion mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- It has a general regulatory effect on the cell cycle.
- It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen).
- It elicits shedding of CD23.
- It downregulates the B-cell receptor.
- It induces apoptosis of CD20+ cells.
The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.
Binder et al further described the part of the CD20 molecule that rituximab binds to: amino acids 170-173 and 182-185, which are physically close to each other as a result of a disulfide bond between amino acids 167 and 183.[1]
Adverse events
Serious adverse events, which can cause death and disability, include:[1]
- Severe infusion reactions
- Tumor lysis syndrome, causing acute renal failure
- Infections
- Hepatitis B reactivation
- Other viral infections
- Progressive multifocal leukoencephalopathy (PML)
- Immune toxicity, with depletion of B cells in 70% to 80% of patients with non-Hodgkins lymphoma
- Pulmonary toxicity[1]
Other anti CD20 monoclonals
The efficacy and success of Rituximab has led to a few other anti CD20 monoclonal antibodies being developed:
- ocrelizumab, humanized (90%-905% human) B-cell agonist.
- ofatumumab (HuMax-CD20) a fully-human B-cell agonist.[1]
- Third-generation anti-CD20s have a glycoengineered Fc fragment (Fc)[1] with enhanced binding to Fc gamma receptors, which increase ADCC (antibody dependent cellular cytotoxicity).[1] Modifications in the variable regions (variable regions)[1] can enhance apoptosis.
The value of a humanized molecule in oncology has not been demonstrated to this date. Another approach to B lymphocyte diseases is to confront their agonists and the receptors of these agonists. Belimumab is an example of such an approach.
References
External links
Chimeric monoclonal antibodies ("-xi-") | |
|---|---|
| "-tuxi-" (tumor/cancer immunotherapy) | Bavituximab, Cetuximab, Rituximab |
| "-cixi-" (cardiovascular) | Abciximab, Volociximab |
| "-lixi-" (immune system) | Basiliximab, Clenoliximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Teneliximab, Vapaliximab |
| "-mexi-" (melanoma) | Ecromeximab |
| "-baxi-" (bacterial) | Pagibaximab |
fr:Rituximab hu:Rituximab nl:Rituximab ja:リツキシマブ
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
